DICE Therapeutics, Inc. (NASDAQ:DICE – Get Rating) – Stock analysts at Cantor Fitzgerald issued their FY2022 earnings per share estimates for shares of DICE Therapeutics in a research note issued on Wednesday, September 14th. Cantor Fitzgerald analyst P. Agrawal forecasts that the company will earn ($2.19) per share for the year. Cantor Fitzgerald has a "Overweight" rating and a $36.00 price target on the stock. The consensus estimate for DICE Therapeutics' current full-year earnings is ($2.37) per share. Cantor Fitzgerald also issued estimates for DICE Therapeutics' FY2023 earnings at ($3.64) EPS.

A number of other equities research analysts have also recently weighed in on the company. HC Wainwright assumed coverage on DICE Therapeutics in a research note on Monday, July 18th. They issued a "buy" rating and a $40.00 price target on the stock. Stifel Nicolaus assumed coverage on DICE Therapeutics in a report on Tuesday, September 6th. They issued a "buy" rating and a $37.00 price objective on the stock. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat, DICE Therapeutics has an average rating of "Buy" and an average price target of $43.33.

DICE Therapeutics Trading Down 0.2 %

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in DICE. Amalgamated Bank acquired a new stake in shares of DICE Therapeutics during the 1st quarter worth $39,000. Prospera Financial Services Inc acquired a new stake in shares of DICE Therapeutics during the 1st quarter worth $39,000. Legal & General Group Plc grew its holdings in shares of DICE Therapeutics by 265.1% during the 2nd quarter. Legal & General Group Plc now owns 4,764 shares of the company's stock worth $74,000 after purchasing an additional 3,459 shares in the last quarter. Virtus ETF Advisers LLC acquired a new stake in shares of DICE Therapeutics during the 4th quarter worth $169,000. Finally, SG Americas Securities LLC acquired a new stake in shares of DICE Therapeutics during the 2nd quarter worth $131,000. 95.42% of the stock is owned by institutional investors and hedge funds.

About DICE Therapeutics

(Get Rating)

DICE Therapeutics, Inc, a biopharmaceutical company, builds various oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. Its platform DELSCAPE, is designed to discover selective oral small molecules to modulate protein-protein interactions (PPIs) as effectively as systemic biologics.

Featured Articles

• Get a free copy of the StockNews.com research report on DICE Therapeutics (DICE)
• Stock Market: 3 Islands Of Strength In A Sea Of Red
• 3 Banks Worth Considering For Q4
• MarketBeat: Week in Review 9/12 – 9/16
• Is There a Cure for What is Ailing Teladoc Stock?
• No One Told These 3 Stocks It's a Down Week

Receive News & Ratings for DICE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DICE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.